The global radiodermatitis market size was estimated at USD 310.9 million in 2016 and is anticipated to grow at a CAGR of 4.0% throughout the forecast period. The market is predominantly driven by growing number of patients suffering from radiodermatitis as an adverse effect of radiation therapy. This has raised high clinical urgency to counter this adverse effect, leading to an unprecedented demand for radiodermatitis treatment products. Consequentially, a significant increase has been observed in the adoption of radiodermatitis products, to improve quality of life, thereby resulting in rapid market progression.
According to statistics presented by the American Society for Radiation Oncology, approximately 95% of patients receiving radiation therapy suffer from some degree of radiodermatitis whereas 85% of the total patient base experience severe to moderate radiodermatitis that requires intensive treatment. This is expected to boost the utilization of radiodermatitis products globally.
U.S. radiodermatitis market by product, 2014 - 2025 (USD Million)
Rising number of public &private healthcare organizations consistently striving to promote awareness about radiodermatitis management and treatment is one of the high impact rendering drivers for this market. In addition, these organizations issue guidelines and recommendations to treat the condition efficiently, which is anticipated to broaden the scope for growth throughout the forecast period.
For instance, BC Cancer Agency, an agency of the Provincial Health Services Authority, issued guidelines on radiodermatitis symptom management and information pertaining to radiodermatitis risk factors. This is anticipated to promote awareness with respect to assessment & treatment procedures and general skincare recommendations, thereby fueling growth potential.
Rising number of clinical studies conducted to evaluate the efficacy of a wide array of radiodermatitis treatment products for treatment are anticipated to expand the product pipeline and present the market with lucrative growth opportunities. For instance, in 2010, products such as Aquaphor, Calendula cream, RadiaCare, and Biafine were studied for efficacy in minimization of high degree radiation burns.
In 2016, the topical product segment captured the largest share of over 70.0%. The substantial share is presumed to be a consequence of benefits associated with topical products. These benefits include easy application, availability, and high cost-efficiency, which are predicted to be some of the major factors fueling the adoption of these products over the previous years.
Moreover, topical products reduce the risk of microbial transmission and shield the skin against abrasive materials. Corticosteroids, hydrophilic creams, and topical antibiotics are some of the major products under this segment. Corticosteroids accounted for the largest share amongst topical agents as a consequence of being considered as a gold standard in the treatment of inflammatory skin conditions, thereby encouraging their adoption for the treatment of radiodermatitis.
Dressings are anticipated to attain moderate growth rate over the coming years owing to the presence of a wide array of products in the market. These products include foam-based, hydrogel & hydrocolloid, silicone-coated, silver-leaf dressings, and others. Dressings have been found to be sufficient for effective treatment of various grades of radiation burns, which is anticipated to fuel their adoption over the coming years.
Hydrogel & hydrocolloid dressings are increasingly being used in the treatment of radiation burns owing to benefits associated with it. These benefits include high degree of protection against infection & bacterial growth, expedited healing, and minimal pain. In addition, availability of a wide array of these products, which cater to different requirements of patients, is expected to broaden the future growth prospects for this segment.
Retail pharmacy held the largest share in the distribution channel segment in 2016. The substantial share can be attributed to high accessibility and affordability associated with retail stores. Affordability is a result of drug cost reimbursement that urges patients to rely on retail pharmacies, thus accentuating market growth potential.
Online pharmacies are anticipated to witness exponential growth rate throughout the forecast period due to various advantages such as increased convenience for patients who’re unwilling to purchase medicines from retail or hospital pharmacies.
Moreover, high prevalence of chronic diseases has led to a gap in the demand and supply of drugs of high importance. These factors accentuate the demand for online pharmacies throughout the forecast period.
Global radiodermatitis market share by distribution channel, 2016 (%)
With the help of online pharmacies, order procurement and tracking by the customer becomes convenient. In addition, associated supply chain management (SCM) eliminates some of the market intermediaries, which reduces the overall drug price, hence driving the inclination of the customers toward online medicine purchase.
In 2016, Asia Pacific captured a dominant share of the market. The expanding cancer patient base present across this region serves as a key contributor toward substantial share captured by this region. In addition, extensive collaborations undertaken by key players for increasing their product portfolio expansion capabilities are responsible for the greater share captured by this region.
Moreover, established pharmaceutical companies in this region are extensively involved in the commercialization of their products and promotion of their usage amongst the end users. Favorable government initiatives that support research activities and increase in outsourcing by developed economies serve as key growth impelling factors for this region.
North America held the second largest share of the radiodermatitis market. This market is predominantly driven by high R&D investment deployed by global players and their focus to attain a competitive position in the market. In addition, high disposable income, and presence of sophisticated healthcare infrastructure are responsible for the significant growth opportunities across the region.
The competitive environment is marked by key players extensively implementing sustainability strategies. The major players, 3M Healthcare; ConvaTec, Inc.; Mölnlycke Health Care AB; and Smith & Nephew cumulatively capture dominant share of the radiodermatitis market. These companies are consistently focusing on strategies such as mergers & acquisitions, new product development initiatives, and geographical expansion.
For instance, in September 2016, ConvaTec launched a new product FoamLite, a thin film, breathable dressing having silicone adhesives, thus increasing its silicone foam dressing product range for burn treatment including radiation burns. This initiative is anticipated to help the company expand its share during the future period.
Similarly, in May 2016, ConvaTec launched new sizes for its product, AQUACEL Foam dressings. This product launch was a step undertaken to increase product penetration, expand geographical presence, and cater to a larger patient base. The initial launch of this product was done in France, the UK, Malaysia, Canada, Bulgaria, the Netherlands, New Zealand, the U.S., and the Nordic countries.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, UK, Japan, China, India, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global radiodermatitis market on the basis of product, distribution channel, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Hydrogel & hydrocolloid dressings
No sting barrier film
Honey impregnated gauze
Silicone coated dressings
Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
b. The global Radiodermatitis market size was estimated at USD 347.2 million in 2019 and is expected to reach USD 360.8 million in 2020.
b. The global Radiodermatitis market is expected to grow at a compound annual growth rate of 4.0% from 2018 to 2025 to reach USD 442.1 million by 2025.
b. Asia Pacific dominated the Radiodermatitis market with a share of 45% in 2019. This is attributable to expanding cancer patient base in the region , extensive collaborations by key players, favorable government initiatives and increase in outsourcing in the region.
b. Some key players operating in the Radiodermatitis market include 3M Healthcare; ConvaTec, Inc.;Mölnlycke Health Care AB; and Smith & Nephew. lence of radiodermatitis due to radiotherapy treatment, Rising number of public & private healthcare organizations and Rising number of clinics.
b. Key factors that are driving the market growth include the prevalence of radiodermatitis due to radiotherapy treatment, Rising number of public & private healthcare organizations, and rising number of clinical studies conducted to expand the product pipeline.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.